MedTrace Logo

Long-Term Oral Acyclovir Usage to Prevent Herpes Zoster Virus Infection After Bone Marrow Transplant

NCT00209352 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2007-12-21

No results posted yet for this study

Summary

The objective of this study is to prevent reactivation of herpes zoster during the first year after transplant.

Conditions

  • VZV Infection After Bone Marrow Transplantation

Interventions

DRUG

Acyclovir

Sponsors & Collaborators

  • Burroughs Wellcome

    collaborator INDUSTRY

  • National Institutes of Health (NIH)

    collaborator NIH

  • Fred Hutchinson Cancer Center

    lead OTHER

Principal Investigators

  • Michael Boeckh, MD · Fred Hutchinson Cancer Center

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1985-06-30
Completion
2004-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00209352 on ClinicalTrials.gov